Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.

Pain Med · 2023 · PMC10628981 · PMID 37302106

Europe PMC DOI

hedged sentence

0.3000

closest p · 6.0× alpha

0.3000

boldest claim

The sentences

did not reach statistical significanceP = .3not close (p > 0.1)

Quality of life was clinically improved in the patients who took LDN compared with the placebo group, though this did not reach statistical significance ( P = .3).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.